Clinical Trials Logo

Filter by:
NCT ID: NCT05869955 Recruiting - Clinical trials for Systemic Lupus Erythematosus

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases

Start date: September 13, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases.

NCT ID: NCT05869838 Recruiting - Colonic Polyp Clinical Trials

A Clinical Study on Endoscopic and Histopathological Outcomes of Screening and Surveillance Colonoscopies

CODACO
Start date: March 12, 2024
Phase:
Study type: Observational

The objective of this study is to collect colonoscopy data for use in the development and testing of artificial intelligence (AI) devices for colonoscopies.

NCT ID: NCT05867927 Recruiting - GYN Disorders Clinical Trials

GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications

GENERATE
Start date: October 25, 2023
Phase:
Study type: Observational

GENERATE - Next GENERATion of GynEcological Surgery - Robotic Assisted Surgery in Gynecological Indications Generate real-world evidence in the use of the da Vinci Xi/X Surgical Systems for gynecological indications within the German health care system.

NCT ID: NCT05867537 Recruiting - Clinical trials for Reduction of Intestinal Inflammatory Activity

Proof of Concept Human Study: Dietary Intervention to Modify Intestinal Inflammation in IBD

Start date: January 18, 2023
Phase: N/A
Study type: Interventional

The objective of this clinical study is to demonstrate efficacy and feasibility of a long-term dietary intervention to modify intestinal inflammation in high-risk patient cohorts. To this end a 78 weeks wheat protein-free diet will be administered in patients with inflammatory bowel disease (IBD) with and without associated primary sclerosing cholangitis (PSC-IBD).

NCT ID: NCT05867186 Recruiting - Pediatric Oncology Clinical Trials

Fit to Fight Childhood Cancer

Kolibri
Start date: June 20, 2023
Phase:
Study type: Observational

The aim of the study is to investigate the influence of exercise on physical performance and psychosocial aspects in children and adolescents with cancer during and after treatment.

NCT ID: NCT05865886 Recruiting - Cystic Fibrosis Clinical Trials

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairaflyâ„¢)

Start date: January 31, 2024
Phase: Phase 2
Study type: Interventional

This study is open to adults aged 18 years and older with cystic fibrosis bronchiectasis. The purpose of this study is to find out whether a medicine called BI 1291583 is tolerated by people with cystic fibrosis bronchiectasis. Participants are put randomly into 2 groups. One group takes BI 1291583 tablets and the other group takes placebo tablets. Placebo tablets look like BI 1291583 tablets but do not contain any medicine. Participants in both groups take 1 tablet once a day for 12 weeks. Participants have twice the chance of being placed in the BI 1291583 group than in the placebo group. Participants are in the study for about 6 months. During this time, they visit the study site 7 times. At the visits, the doctors check the health of the participants and note any health problems that could have been caused by BI 1291583.

NCT ID: NCT05862909 Recruiting - Clinical trials for Congenital Heart Disease

Efficacy of a Web-Based Emotion Regulation Intervention for Patients With Congenital Heart Disease

Start date: August 5, 2022
Phase: N/A
Study type: Interventional

Congenital heart disease (CHD) is associated with daily stressors and functional impairments that can cause negative emotions. Emotion regulation abilities may determine whether people with CHD develop psychopathology or adapt to the illness-related regulatory demands. This three-arm randomized clinical trial evaluates the efficacy of emotion regulation interventions in individuals with CHD. Patients with CHD over 18 years will be randomly assigned to a CHD-specific web-based emotion regulation intervention, a general web-based emotion regulation intervention, or a waitlist control group with delayed intervention access (8 weeks). The interventions are based on cognitive behavioral therapy, including everyday emotion regulation exercises and psychoeducation via video and audio files. Four and eight weeks after baseline, emotion regulation, well-being, depression, anxiety, perceived stress, life satisfaction, and illness identity will be assessed. Both interventions are expected to improve emotion regulation abilities, well-being, depressive symptoms, anxiety, perceived stress, life satisfaction, and illness identity four and eight weeks after baseline compared to the waitlist control group. The disease-specific intervention is hypothesized to be superior as it targets everyday emotional problems in CHD patients.

NCT ID: NCT05861843 Recruiting - Clinical trials for Alcohol Use Disorder

Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure

CRAVE
Start date: September 23, 2023
Phase:
Study type: Observational

Alcohol use disorder (AUD) is a burdensome clinical disorder with high relapse rates. Virtual Reality (VR)-based therapeutic and diagnostic approaches have received increasing attention in the treatment of AUD but evidence on the induction of craving via VR scenarios is still needed. Craving for alcohol is associated with psychological and physiological responses. This single-arm clinical study will be conducted including n=60 patients with AUD. Using a head-mounted display (HMD), patients will be confronted with three different VR scenarios (neutral vs. two target situations) while heart rate, heart rate variability (HRV), pupillometry and electrodermal activity (EDA) will be measured continuously. Subjective craving levels will be assessed pre-/during/post-exposure to each VR scenario.

NCT ID: NCT05861583 Recruiting - Lipedema Clinical Trials

Evaluation of Lipoedema Tissue Transcriptome

Start date: January 1, 2023
Phase:
Study type: Observational

Lipoedema is a chronic painful disease with a fat distribution disorder affecting women. It is probably aggravated by hormonal changes. It is also discussed that a genetical predisposition might be a risk factor for developing lipoedema. The mechanisms leading to lipoedema are mostly unknown. The aim of this study is to identify molecular mechanisms and changes of the RNA-Expression pattern causing lipoedema by comparing the transcriptome of subcutaneous tissue of lipoedema patients vs. healthy subcutaneous tissue.

NCT ID: NCT05859724 Recruiting - Atopic Dermatitis Clinical Trials

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Start date: May 10, 2023
Phase: Phase 1
Study type: Interventional

This is a randomized, double-blind, placebo-controlled, single- and multiple ascending dose study of subcutaneous (SC) administration of NM26-2198 in healthy volunteers and adult patients with moderate to-severe AD to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single (SAD) and multiple doses (MAD) of NM26-2198.